{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05885464",
      "title": "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia",
      "start_date": "2023-05-25",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Beam Therapeutics Inc."
    },
    {
      "nct_id": "NCT06389877",
      "title": "A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Alpha 1-Antitrypsin Deficiency",
      "start_date": "2024-06-19",
      "completion_date": "2027-08",
      "enrollment": 0,
      "sponsor": "Beam Therapeutics Inc."
    },
    {
      "nct_id": "NCT06071377",
      "title": "Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Sickle Cell Trait",
      "start_date": "2023-04-01",
      "completion_date": "2027-02",
      "enrollment": 0,
      "sponsor": "National Alliance for Sickle Cell Centers"
    },
    {
      "nct_id": "NCT05456880",
      "title": "BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Sickle Cell Disease",
      "start_date": "2022-08-30",
      "completion_date": "2028-02",
      "enrollment": 0,
      "sponsor": "Beam Therapeutics Inc."
    },
    {
      "nct_id": "NCT06934382",
      "title": "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "T-Cell Acute Lymphoblastic Leukemia/Lymphoma",
      "start_date": "2025-04-29",
      "completion_date": "2031-05-30",
      "enrollment": 0,
      "sponsor": "Stephan Grupp MD PhD"
    },
    {
      "nct_id": "NCT07304791",
      "title": "This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy Subjects, Healthy Participant Study",
      "start_date": "2025-10-27",
      "completion_date": "2026-05-29",
      "enrollment": 0,
      "sponsor": "Beam Therapeutics Inc."
    },
    {
      "nct_id": "NCT06735755",
      "title": "A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Glycogen Storage Disease Type Ia",
      "start_date": "2024-12-06",
      "completion_date": "2027-12-30",
      "enrollment": 0,
      "sponsor": "Beam Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "PHASE1, PHASE2": 4,
      "": 1,
      "PHASE1": 2
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 5
    },
    "active_trials": 7,
    "completed_trials": 0,
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency",
      "Glycogen Storage Disease Type Ia",
      "Healthy Subjects, Healthy Participant Study",
      "Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia",
      "Sickle Cell Disease",
      "Sickle Cell Trait",
      "T-Cell Acute Lymphoblastic Leukemia/Lymphoma"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:27.766300",
    "search_query": "Beam Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=Beam+Therapeutics+Inc."
  }
}